Skip to main content
. Author manuscript; available in PMC: 2022 Nov 15.
Published in final edited form as: Int J Radiat Oncol Biol Phys. 2021 Jul 21;111(4):907–916. doi: 10.1016/j.ijrobp.2021.07.035

Fig. 2.

Fig. 2.

Risks of grade ≥3 cardiac adverse events (A and B) and overall survival (C and D) stratified by serum high-sensitivity cardiac troponin T (hs-cTnT) levels: baseline hs-cTnT levels <10 ng/L vs. ≥10 ng/L and hs-cTnT delta (peak minus baseline) during chemoradiation therapy <5 ng/L vs. ≥5 ng/L.